Expert Insights

At the 2023 ASCO Annual Meeting, Kathleen Moore, MD, shares results from the MIRASOL trial, evaluating mirvetuximab soravtansine among patients with folate recetor alpha-high platinum-resistant ovarian cancer.

At the 2023 ASCO meeting, Reid Merryman, MD, shares data assessing the efficacy and safety of epcoritamab plus rituximab and lenalidomide among patients with R/R FL.

At the 2023 World Congress on Gastrointestinal Cancers, Eileen O’Reilly, MD, discusses the existing standards and upcoming options for the treatment of pancreatic cancer.

At the 2023 ASCO Annual Meeting, Tsz Lun Yeung, MD, presented data which found extended dosing with the IAP inhibitor xevanipant improved the efficacy of radiotherapy in preclinical models of head and neck squamous cell carcinoma.

At the 2023 ASCO Annual Meeting, Paul Paik shared the long-term outcomes of tepotinib for patients with MET exon 14 skipping non-small cell lung cancer.

At the 2023 ASCO Annual Meeting, Ticiana Leal, MD, discussed the results of the phase 3 LUNAR study, which found that the addition of tumor treating fields to standard of care improved overall survival among patients with metastatic non-small...

At the 2023 World Congress on Gastrointestinal Cancers, Van Morris, MD, presented results from a phase 2 study evaluating the addition of ipilimumab to nivolumab for patients with previously treated, unresectable or metastatic squamous cell...

According to a study presented at the 2023 World Congress on Gastrointestinal Cancers, different microbes in the colorectal cancer tumor microenvironment were found to increase immune activity and potentially have an immunosuppressive effect.

According to a study presented at the 2023 World Congress on Gastrointestinal Cancers, there were distinct mutational differences noted between appendiceal adenocarcinoma and colorectal cancer.